LIFE (Losartan Intervention for End Point Reduction) Studies in Hypertensive Patients in Reducing Various CV Morbidities and Mortalities Including Stroke Compared Atenolol
![](https://www.texilajournal.com/thumbs/article/Hypertensive.jpg)
Abstract:
Stroke is the second leading cause of cardiovascular
morbidity and mortality worldwide with long term disability in developed
countries. Various risk factors lead to progression of stroke, they include
hypertension, atrial fibrillation, new onset of diabetes, isolated systolic
hypertension(ISH) & left ventricular hypertrophy. Among these risk factors,
Hypertension is considered as major risk factor for myocardial infarction
previously but now-a-days it is consider as the greatest risk factor for the
stroke. Various antihypertensive agents which either as mono therapy or in
combinations are use to reduce above cardiovascular (CV) morbidities and
mortalities including different stroke outcomes.
Recently losartan,
AT-2(angiotensin-2) receptor antagonist which is acting on renin angiotensin
system (RAS) is considered as first line agent to reduce different CV
morbidities and mortalities compared to other conventional B-blockers and
Thiazide diuretic combinations. Various “LIFE (losartan intervention for end point
reduction) studies” were conducted in hypertensive patients which show better
efficacy profile of losartan in reducing various CV morbidities and mortalities
including stroke compared to atenolol.
References:
[1.] Bang, C. N., Gerdts, E., Aurigemma, G. P., Boman, K.,
Dahlöf, B., Roman, M. J., Køber L., Wachtell, K., Devereux, R. B. (2013).
Systolic left ventricular function according to left ventricular concentricity
and dilatation in hypertensive patients: the Losartan Intervention For Endpoint
reduction in hypertension study. J Hypertens, 31(10), 2060-8.
[2.] Fossum, E., Moan, A., Kjeldsen, S. E., Devereux, R.
B., Julius, S., Snapinn, S. M., Edelman, J. M., Faire, U., Fyhrquist, F.,
Ibsen, H., Kristianson, K., Lederballe-Pedersen ,O., Lindholm, L. H., Nieminen,
M. S., Omvik, P., Oparil, S., Wedel, H., Dahlöf, B. (2005). The Effect of
Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients
With Hypertension Taking Aspirin The Losartan Intervention for Endpoint
Reduction in Hypertension (LIFE)Study. J Am Coll Cardiol;46:770 –775.
[3.] Goldberg, A. I., Dunlay, M. C., and Sweet, C. S.
(1995). Safety and Tolerability of Losartan Potassium, an Angiotensin II
Receptor Antagonist, Compared With Htdrochlorothirrzide, Atenolol, Felodiprne
ER. And Angiotensin-Converting Enzyme Inhibitors for the Treatment of Systemic
Hypertension. Am J Cardiol, 75,793-795.
[4.] Greve, A. M., Olsen, M. H., Bella, J. N., Lønnebakken
M. T., Gerdts, E., Okin P. M., Palmieri V., Boman K., Nieminen M. S., Omvik P.,
Dahlöf, B., Devereux, R. B., Wachtell, K. (2012). Contrasting hemodynamic
mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE
study. Am J Hypertens, 25(9), 1017-23.
[5.] Kizer, J. R., Dahlof, B., Kjeldsen, S. E., Julius, S.,
Beevers, G., Faire, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lindholm, H.
M., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Wachtell, K., Edelman,
J. M., Snapinn, S. M., Harris, K. E., Devereux, R. B.,(2005). Stroke Reduction
in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus
Atenolol The Losartan Intervention For Endpoint Reduction in Hypertension Study.
J. Am. Heart Assoc. Hypertension, 45, 46-52.
[6.] Ruwald A. C., Westergaard, B., Sehestedt, T.,
Kjeldsen, S. E., Lindholm, L. H., Wachtell, K., Devereux, R. B., Ibsen, H.,
Nieminen, M. S., Dahlöf, B., Olsen, M. H. (2012). Losartan versus
atenolol-based antihypertensive treatment reduces cardiovascular events
especially well in elderly patients: the Losartan Intervention For Endpoint
reduction in hypertension (LIFE) study. J Hypertens, 30(6), 1252-9.
[7.] Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H.,
Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L.
H., Nieminen, M. S., Devereux, R. B.(2005). Angiotensin II receptor blockade
reduces new-onset atrial fibrillation and subsequent stroke compared to
atenolol: The Losartan Intervention For End point reduction in hypertension
(LIFE) study. J. Am. Coll. Cardiol, 45, 712-719.